Dr. Rod Mahmoudizad, MD

Dr. Mahmoudizad practices at Advanced Dermasurgery Associates in Katy, Texas.

Dr. Mahmoudizad's NPI, 1992084735, was assigned on August 10, 2011. Dr. Mahmoudizad graduated from UTMB Health in 2011. Dr. Mahmoudizad holds Texas license Q8950.

Dr. Mahmoudizad's primary practice is Advanced Dermasurgery Associates, at 21800 Katy Fwy, Katy, TX 77449 in Harris County. The practice phone is (214) 987-3376.

Dr. Mahmoudizad's primary practice is Advanced Dermasurgery Associates in Katy, Texas. The medical group on file is Dallas Associated Dermatologists. Dmand AI also links Dr. Mahmoudizad to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mahmoudizad practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Mahmoudizad's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Mahmoudizad is board certified in dermatology by the American Board of Dermatology. Dr. Mahmoudizad is licensed in Texas.

Dmand AI lists benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes and contact dermatitis among the conditions Dr. Mahmoudizad treats.

CMS data shows 1,948 Medicare services from Dr. Mahmoudizad across 26 procedure codes in 2024, for 591 Medicare patients. Medicare paid $573,515 for them. Every service was in an office.

CMS counts 591 Medicare patients who saw Dr. Mahmoudizad in 2024. The largest group is 65 to 74, with 287 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mahmoudizad's median patient age at 73, with 36% women.

In 2024, Dr. Mahmoudizad wrote 1,317 Medicare Part D claims for 979 patients. 100% of them were for generic drugs. CMS names the drug for 1,254 of them, across 4 drugs with 11 or more claims each, at $8,100 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Mahmoudizad for performance year 2024, reported individually. Dr. Mahmoudizad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 170 procedures of melanoma (skin cancer) excision by Dr. Mahmoudizad, more than 96% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Mahmoudizad, published from 2010 to 2015. 2014 was the busiest year, with 2. The most frequent topics are Skin Neoplasms. Dr. Mahmoudizad's most frequent co-authors are Katherine Hutka Fiala, MD, Ronald E. Grimwood, MD and Jesus Nunez, MD.

CMS Open Payments shows 190 general payments to Dr. Mahmoudizad from 22 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $667.

Dr. Mahmoudizad graduated from UTMB Health in 2011.

Dr. Mahmoudizad is in network with 18 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.